Unicycive Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Mountain View, CA
UNCY chart
What traders are saying about $UNCY
Latest postsUnicycive Therapeutics, Inc. news
- Unicycive Therapeutics at Guggenheim conference: launch plan takes shape By Investing.com
Investing.com India ·
- Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
investorshub.advfn.com ·
- A kidney-treatment developer's CEO is set to speak Nov. 10
Stock Titan ·
- Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, PDUFA Date of March 25, 2027
investorshub.advfn.com ·
- Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Yahoo Finance ·
- Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
Yahoo Finance ·
- Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
Yahoo Finance ·
- Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Unicycive Therapeutics shares rise after second-quarter loss beats forecasts
investorshub.advfn.com ·
- Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Yahoo Finance ·
- Hyperphosphatemia Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Novel Therapeutics and Rising CKD Burden | DelveInsight
Yahoo Finance ·
- Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
Yahoo Finance ·
Unicycive Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | $675,000 | $951,000 |
| Net income | -$26.6M | -$36.7M | -$30.5M | -$18.1M |
| Diluted EPS | $-1.67 | $-5.65 | $-1.28 | $-1.20 |
| Total assets (year end) | $49.1M | $31.7M | $14.2M | $2.8M |
| Cash and equivalents (year end) | $29.2M | $26.1M | – | $455,000 |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Unicycive Therapeutics, Inc.
- Ticker
- UNCY (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Mountain View, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1766140
- Former names
- Unicycive Therapeutics, Inc.
Frequently asked questions
What exchange is Unicycive Therapeutics, Inc. listed on?
Unicycive Therapeutics, Inc. trades on the Nasdaq under the ticker symbol UNCY.
What industry is Unicycive Therapeutics, Inc. in?
Unicycive Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Unicycive Therapeutics, Inc. headquartered?
Unicycive Therapeutics, Inc.'s business address on file with the SEC is in Mountain View, CA.
When does Unicycive Therapeutics, Inc.'s fiscal year end?
Unicycive Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Unicycive Therapeutics, Inc. report?
Unicycive Therapeutics, Inc. reported $675,000 in revenue for calendar year 2023, according to its SEC filings.